ES2187533T3 - Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina. - Google Patents
Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.Info
- Publication number
- ES2187533T3 ES2187533T3 ES94928623T ES94928623T ES2187533T3 ES 2187533 T3 ES2187533 T3 ES 2187533T3 ES 94928623 T ES94928623 T ES 94928623T ES 94928623 T ES94928623 T ES 94928623T ES 2187533 T3 ES2187533 T3 ES 2187533T3
- Authority
- ES
- Spain
- Prior art keywords
- sub
- group
- mammer
- reduction
- ilamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
METODO PARA EL TRATAMIENTO DE UN MAMIFERO QUE COMPRENDE LA ADMINISTRACION A UN MAMIFERO DE UNA CANTIDAD EFECTIVA PARA PROPORCIONAR EL EFECTO TERAPEUTICO DESEADO EN EL MAMIFERO, DE UN COMPUESTO SELECCIONADO DEL GRUPO QUE SE COMPONE DE AQUELLOS QUE TIENEN LA FORMULA (I), Y SALES ACIDAS DE ADICION FARMACEUTICAMENTE ACEPTABLES DEL MISMO Y MEZCLAS DEL MISMO, EN DONDE R{SUB,1} Y R{SUB,2} SON SELECCIONADOS DEL GRUPO COMPUESTO POR RADICALES ALQUILO QUE CONTIENEN DE 1 A 4 ATOMOS DE CARBONO Y RADICALES ALCOXI QUE CONTIENEN DE 1 A 4 ATOMOS DE CARBONO, EL GRUPO 2-IMIDAZOLIN-2-ILAMINO PUEDE ESTAR EN CUALQUIERA DE LAS POSICIONES 5-,6-,7 U 8 DEL NUCLEO DE QUINOXALINA, Y R{SUB,3}, R{SUB,4} Y R{SUB,5}, CADA UNO DE ELLOS ESTA SITUADO EN LAS SITUACIONES RESTANTES 5-, 6-, 7-, U 8, DEL NUCLEO DE QUINOXALINA Y ES SELECCIONADO INDEPENDIENTEMENTE DEL GRUPO CONSISTENTE EN CL, BR, H Y RADICALES ALQUILO QUE CONTIENEN DE 1 A 3 ATOMOS DE CARBONO. DICHOS COMPUESTOS, CUANDO SE ADMINISTRAN A UN MAMIFERO, PROPORCIONAN LOSEFECTOS TERAPEUTICOS DESEADOS, COMO LA REDUCCION DEL DOLOR PERIFERICO, LA ANESTESIA DEL SISTEMA NERVIOSO CENTRAL, LA CONSTRICCION DE UNO O MAS VASOS SANGUINEOS, LA REDUCCION O PREVENCION DE AL MENOS UN EFECTO DE LA ISQUEMIA, DESCONGESTION DE UNO O MAS CONDUCTOS NASALES, REDUCCION DE AL MENOS UN EFECTO DE LAS ENFERMEDADES INFLAMATORIAS, AUMENTO DEL FLUJO RENAL FLUIDO, Y ALTERACION DEL INDICE DE FLUIDO EN EL TRACTO GASTROINTESTINAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13571693A | 1993-10-13 | 1993-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2187533T3 true ES2187533T3 (es) | 2003-06-16 |
Family
ID=22469328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94928623T Expired - Lifetime ES2187533T3 (es) | 1993-10-13 | 1994-09-19 | Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina. |
Country Status (8)
Country | Link |
---|---|
US (7) | US5552403A (es) |
EP (2) | EP1285657A3 (es) |
JP (3) | JP3683908B2 (es) |
AU (1) | AU688380B2 (es) |
CA (1) | CA2173974C (es) |
DE (1) | DE69431880T2 (es) |
ES (1) | ES2187533T3 (es) |
WO (1) | WO1995010280A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
CN1155383C (zh) | 1995-12-21 | 2004-06-30 | 阿尔康实验室公司 | 某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途 |
US6465713B1 (en) * | 1997-06-30 | 2002-10-15 | Mcneil-Ppc, Inc. | Tampon having an apertured film cover |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
ATE291907T1 (de) * | 1998-10-20 | 2005-04-15 | Omeros Corp | Spülende lösung und methoden zur hemmung von schmerzen und entzündungen |
US7973068B2 (en) | 1998-10-20 | 2011-07-05 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
US6242442B1 (en) | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
US6294553B1 (en) * | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
PL361027A1 (en) * | 2000-07-14 | 2004-09-20 | Allergan,Inc. | Compositions containing therapeutically active components having enhanced solubility |
US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
JP4927298B2 (ja) | 2000-07-14 | 2012-05-09 | アラーガン、インコーポレイテッド | α−2−アドレナリンアゴニスト成分を含有する組成物 |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
EP2113246B1 (en) | 2003-08-07 | 2016-06-22 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
US20070042951A1 (en) * | 2003-10-08 | 2007-02-22 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
DE102004024011A1 (de) * | 2004-05-14 | 2005-12-01 | Bayer Chemicals Ag | Difluorbenzo-1,3-dioxole |
AU2006311577B2 (en) | 2005-11-09 | 2013-02-07 | Zalicus Inc. | Methods, compositions, and kits for the treatment of medical conditions |
US7926280B2 (en) * | 2007-05-16 | 2011-04-19 | Pratt & Whitney Canada Corp. | Interface between a combustor and fuel nozzle |
US20080293728A1 (en) * | 2007-05-18 | 2008-11-27 | Mcintire Gregory L | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions |
US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
US20100202979A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
US20110003823A1 (en) * | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
US20100029662A1 (en) * | 2008-08-01 | 2010-02-04 | Alpha Synergy Development, Inc. | Vasoconstriction compositions and methods of use |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
EP2552448B1 (en) | 2010-03-26 | 2019-04-24 | Galderma Research & Development | Improved compositions comprising brimonidine for safe and effective treatment of telangiectasia |
US8513247B2 (en) | 2010-03-26 | 2013-08-20 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
CN102883708A (zh) | 2010-04-07 | 2013-01-16 | 阿勒根公司 | 用于眼用组合物的防腐剂联合 |
CN102883709A (zh) | 2010-04-07 | 2013-01-16 | 阿勒根公司 | 用于眼用制剂的防腐组合物联合 |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
SG189896A1 (en) | 2010-10-21 | 2013-06-28 | Galderma Sa | Brimonidine gel compositions and methods of use |
RU2014106364A (ru) * | 2011-07-25 | 2015-08-27 | Аллерган, Инк. | Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2 |
CN103889417A (zh) | 2011-10-19 | 2014-06-25 | 高德美国际公司 | 减少与全身使用5型磷酸二脂酶抑制剂有关的面部潮红的方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE230960C (es) * | ||||
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
GB1463520A (en) * | 1974-09-06 | 1977-02-02 | Pfizer Ltd | Process for the production of imidazolines |
US4188393A (en) * | 1977-04-22 | 1980-02-12 | Sandoz Ltd. | Treating spastic conditions or relaxing muscles |
US4656291A (en) * | 1985-03-15 | 1987-04-07 | Mcneilab, Inc. | Process for producing amidine sulfonic acids |
US4908387A (en) * | 1988-06-06 | 1990-03-13 | The Regents Of The University Of California | Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis |
US5034406A (en) * | 1989-09-26 | 1991-07-23 | Allergan, Inc. | Method for reducing or maintaining intraocular pressure |
US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5204347A (en) * | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
US5198442A (en) * | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5231096A (en) * | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5237072A (en) * | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
US5130441A (en) * | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
-
1994
- 1994-09-19 DE DE69431880T patent/DE69431880T2/de not_active Expired - Lifetime
- 1994-09-19 CA CA002173974A patent/CA2173974C/en not_active Expired - Fee Related
- 1994-09-19 WO PCT/US1994/010569 patent/WO1995010280A1/en active IP Right Grant
- 1994-09-19 ES ES94928623T patent/ES2187533T3/es not_active Expired - Lifetime
- 1994-09-19 JP JP51181295A patent/JP3683908B2/ja not_active Expired - Fee Related
- 1994-09-19 EP EP02079577A patent/EP1285657A3/en not_active Withdrawn
- 1994-09-19 EP EP94928623A patent/EP0723447B1/en not_active Expired - Lifetime
- 1994-09-19 AU AU77988/94A patent/AU688380B2/en not_active Ceased
- 1994-10-31 US US08/332,029 patent/US5552403A/en not_active Expired - Lifetime
-
1995
- 1995-02-15 US US08/390,265 patent/US5561132A/en not_active Expired - Lifetime
- 1995-06-02 US US08/458,949 patent/US5587376A/en not_active Expired - Lifetime
-
1996
- 1996-04-19 US US08/636,740 patent/US5756503A/en not_active Expired - Lifetime
- 1996-08-07 US US08/693,745 patent/US5703077A/en not_active Expired - Lifetime
- 1996-08-07 US US08/695,103 patent/US5714486A/en not_active Expired - Lifetime
-
1997
- 1997-06-23 US US08/880,473 patent/US5773440A/en not_active Expired - Lifetime
-
2003
- 2003-04-23 JP JP2003118533A patent/JP2003277264A/ja active Pending
-
2005
- 2005-04-01 JP JP2005106391A patent/JP2005232186A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0723447A1 (en) | 1996-07-31 |
US5703077A (en) | 1997-12-30 |
US5756503A (en) | 1998-05-26 |
EP0723447B1 (en) | 2002-12-11 |
US5587376A (en) | 1996-12-24 |
EP1285657A2 (en) | 2003-02-26 |
WO1995010280A1 (en) | 1995-04-20 |
US5561132A (en) | 1996-10-01 |
AU688380B2 (en) | 1998-03-12 |
DE69431880D1 (de) | 2003-01-23 |
EP1285657A3 (en) | 2003-08-20 |
US5552403A (en) | 1996-09-03 |
US5773440A (en) | 1998-06-30 |
DE69431880T2 (de) | 2003-09-18 |
JP2003277264A (ja) | 2003-10-02 |
JP3683908B2 (ja) | 2005-08-17 |
AU7798894A (en) | 1995-05-04 |
JPH09506338A (ja) | 1997-06-24 |
CA2173974A1 (en) | 1995-04-20 |
CA2173974C (en) | 2006-05-02 |
US5714486A (en) | 1998-02-03 |
JP2005232186A (ja) | 2005-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2187533T3 (es) | Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina. | |
Agarwal et al. | Seizures occurring in pediatric patients receiving continuous infusion of bupivacaine | |
ES2194025T3 (es) | Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares. | |
French et al. | Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors | |
DK0682514T3 (da) | Anvendelse af lokalanæstetiske midler til fremstilling af et lægmiddel til behandling af bronchial astma | |
BR9714677A (pt) | "enantiÈmeros 3-piridila e seu uso como analgésicos" | |
ATE200222T1 (de) | Verfahren zur verwendung von (2-imitazolin-2- ylamino)-chinoxalindeviraten | |
Ebmeyer et al. | Thiopental combination treatments for cerebral resuscitation after prolonged cardiac arrest in dogs. Exploratory outcome study | |
DE3602370A1 (de) | Verwendung von analgetica durch inhalation | |
Riordan et al. | Prolonged curarization in a patient with renal failure | |
Nishikawa et al. | Naloxone attenuates drinking behavior in a schizophrenic patient displaying self-induced water intoxication | |
McCulloch et al. | An intact glutamatergic trigeminal pathway is essential for the cardiac response to simulated diving | |
Downing et al. | Epidural morphine delivered by a percutaneous epidural catheter for outpatient treatment of cancer pain | |
ES2211996T3 (es) | Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis. | |
Takasaki et al. | Blood levels of mepivacaine during continuous epidural anesthesia | |
Neill | Postoperative analgesia following brachial plexus block | |
Davies | Oral diazepam premedication reduces the incidence of post-succinylcholine muscle pains | |
Reiter et al. | Neuroleptic-induced akathisia treated with pindolol | |
Waterman et al. | Malignant hyperthermia: a case report | |
Valley et al. | Relief of recurrent upper extremity sympathetically-maintained pain with contralateral sympathetic blocks: evidence for crossover sympathetic innervation? | |
US4552865A (en) | Psychotropic drugs | |
McFarlain et al. | Comparison of muscle relaxation with placebo medication for anxiety reduction in alcoholic inpatients. | |
Geisz-Everson et al. | Asystole during laryngoscopy of a patient with pleural and pericardial effusions: a case report. | |
Kemeny et al. | The effects on toxicity of circadian patterning of continuous hepatic artery infusion | |
HOPKINSON et al. | Hydrohemothorax following percutaneous internal jugular vein cannulation recognized by intravenous pyelography |